Holen Sie sich die Stockscreener-App
0.7001
4.92%
-0.0312
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SCYX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.7313
Offen:
$0.679
24-Stunden-Volumen:
526.40K
Relative Volume:
0.96
Marktkapitalisierung:
$55.23M
Einnahmen:
$20.60M
Nettoeinkommen (Verlust:
$-8.61M
KGV:
-5.0695
EPS:
-0.1381
Netto-Cashflow:
$-5.28M
1W Leistung:
+5.86%
1M Leistung:
-31.83%
6M Leistung:
+2.52%
1J Leistung:
-10.40%
1-Tages-Spanne:
$0.663
$0.7292
1-Wochen-Bereich:
$0.6328
$0.7367
52-Wochen-Spanne:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Firmenname
Scynexis Inc
Sektor
Telefon
201-884-5485
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.6952 | 58.10M | 20.60M | -8.61M | -5.28M | -0.1381 |
TAK
Takeda Pharmaceutical Co Adr
|
15.88 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.26 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.74 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.66 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.21 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-22 | Eingeleitet | Guggenheim | Buy |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Hochstufung | Needham | Hold → Buy |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-10 | Eingeleitet | ROTH Capital | Buy |
| 2017-05-09 | Herabstufung | Needham | Buy → Hold |
| 2017-03-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-07 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2016-08-17 | Eingeleitet | Guggenheim | Buy |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-08-09 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Eingeleitet | Brean Capital | Buy |
| 2015-12-29 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-06-10 | Eingeleitet | Needham | Buy |
| 2014-05-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2014-05-29 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Scynexis Inc Aktie (SCYX) Neueste Nachrichten
Stock Market Today: S&P 500, Dow, Nasdaq Futures Up Amid US 'Defensive Strikes' On Iran— Elbit Systems, Intuitive Machines, Zscaler In Focus (UPDATED) - Benzinga
SCYNEXIS to implement 1-for-8 reverse stock split - MSN
SCYNEXIS (SCYX) Announces 1-for-8 Reverse Stock Split to Meet Na - GuruFocus
SCYNEXIS announces 1-for-8 reverse stock split effective May 29 - Investing.com UK
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split - TipRanks
SCYNEXIS announces 1-for-8 reverse stock split effective May 29 By Investing.com - Investing.com South Africa
Scynexis stock falls 7% on reverse stock split announcement - Investing.com
SCYNEXIS Announces One-for-Eight Reverse Stock Split - The Manila Times
Biotech SCYNEXIS shrinks share count with 1-for-8 reverse split - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYX: Shareholders approved a reverse stock split and reduction of authorized shares - TradingView
SCYX: Reverse stock split and share reduction approved; no questions or other proposals raised - TradingView
SCYNEXIS (SCYX) approves 1-for-8 reverse stock split and major cut to authorized shares - Stock Titan
SCYNEXIS (SCYX) Falls -7.43% — Watching $0.66 Support 2026-05-18Overbought Alert - Newser
Why did SCYX stock jump 10% in pre-market today? - MSN
Press Releases about SCYNEXIS, Inc.Common Stock - The Chronicle-Journal
CVI Investments and Heights disclose 6.2% stake in SCYNEXIS (SCYX) - Stock Titan
SCYNEXIS (SCYX) price target increased by 20.73% to 4.28 - MSN
SCYNEXIS (SCYX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Financial Overview of SCYX: Cash Position Strengthened - GuruFocus
Scynexis: Q1 Earnings Snapshot - marketscreener.com
Rare-disease biotech SCYNEXIS buys kidney-drug candidate, funds runway to 2029 - Stock Titan
BRIEF-Scynexis Q1 Operating Expenses USD 16.939 Million - TradingView
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
Press Release: SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
SCYNEXIS (SCYX) boosts cash with $40M raise as R&D spend jumps in Q1 2026 - Stock Titan
[EFFECT] SCYNEXIS INC SEC Filing - Stock Titan
Scynexis | SCHEDULE 13G: Others - Moomoo
MSN Money - MSN
SCYNEXIS (NASDAQ: SCYX) registers 87M shares for resale by private‑placement buyers - Stock Titan
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SCYNEXIS Grants Options for 259,500 Shares to New Employees - geneonline.com
Scynexis Deadline Reminder - TMX Newsfile
New SCYNEXIS vice president gets options for 125,000 shares - Stock Titan
SCYX Forecast, Price Target & Analyst Ratings | SCYNEXIS INC (NASDAQ:SCYX) - ChartMill
Finanzdaten der Scynexis Inc-Aktie (SCYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):